Why do the Oncotype DX assay reports include quantitative estrogen receptor (ER) and progesterone receptor (PR) Scores?
Genomic Health’s research has revealed that both ER and PR, as measured using RT-PCR by the Oncotype DX assay, have a wide range of expression across a continuum that is not reported by other methods that are commonly available. Based on this information, and given that the ER and PR scores are generated with the analysis that generates the Recurrence Score result, Genomic Health concluded that reporting the quantitative ER and PR Scores together with the Recurrence Score result as part of the Oncotype DX assay report was appropriate to provide additional insight into the biology of individual tumors. These data are included in reports generated on or after February 1, 2008.
